<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="14406">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00304161</url>
  </required_header>
  <id_info>
    <org_study_id>K23MH067894</org_study_id>
    <secondary_id>K23MH067894</secondary_id>
    <nct_id>NCT00304161</nct_id>
  </id_info>
  <brief_title>Effectiveness of Antidepressant Treatment for Depression in People With Parkinson's Disease</brief_title>
  <official_title>Depression Diagnosis and Treatment in Parkinson Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <authority>United States: Federal Government</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the effectiveness of atomoxetine in reducing symptoms of depression
      in people with Parkinson's disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Depression is a serious medical condition that affects people's thoughts, feelings, and
      ability to function in everyday life. Depression can happen to anyone, but it is more of a
      risk in people with Parkinson's disease, a progressive brain disorder that is caused by a
      loss of dopamine-producing brain cells. As many as half of people with Parkinson's may
      suffer from depression. These individuals experience different symptoms than those who have
      depression alone. For example, they are prone to higher rates of anxiety, sadness without
      guilt or self-blame, and lower suicide rates despite high rates of suicidal thoughts.
      Depression treatment can help people with Parkinson's disease who are depressed to manage
      both diseases and improve the quality of their lives. This study will evaluate the
      effectiveness of atomoxetine, an antidepressant medication, in reducing symptoms of
      depression in people with Parkinson's disease.

      Participants in this double-blind study will be randomly assigned to receive either
      atomoxetine or placebo for 8 weeks. All participants will report to the study site at
      baseline and Weeks 2, 4, and 8. Psychiatric, neuropsychological, and neurological
      assessments will be performed, including evaluations with the Inventory of Depressive
      Symptomatology (IDS) scale and the Clinical Global Impression-Improvement (CGI-I) scale. All
      participants will be offered continued routine psychiatric care with the study physician
      upon completion of the study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2004</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Inventory of Depressive Symptomatology- Clinician Rated (IDS-C) Scale</measure>
    <time_frame>Week 8</time_frame>
    <safety_issue>No</safety_issue>
    <description>The primary measure of depression symptom severity was the Inventory for Depressive Symptomatology-Clinician Rated (IDS-C), a 30-item (scores 0-84, increasing scores indicating greater depression severity) comprehensive instrument that is increasingly used as a primary outcome measure in major depression treatment studies in the general population. An IDS-C score of greater than or equal to 22 was indicative of at least moderate depression. The IDS-C was administered at every study visit. The criteria for the primary measure of treatment response was a &gt;50% decrease in IDS-C score from baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression-Improvement Scale</measure>
    <time_frame>Week 8</time_frame>
    <safety_issue>No</safety_issue>
    <description>The Clinical Global Impression-Improvement scale rates total improvement on a 7 point scale:
= Very much improved
= Much improved
= Minimally improved
= No change
= Minimally worse
= Much worse
= Very much worse
A participant scoring a 1 or 2 is considered a responder on the CGI scale.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">55</enrollment>
  <condition>Depressive Disorder</condition>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>Atomoxetine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive 40-80mgs of atomoxetine orally once daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive placebo treatment once daily; the pill (taken orally) will resemble the atomoxetine pill but will not contain an active drug.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atomoxetine</intervention_name>
    <description>40 to 80 mg orally once daily for 8 weeks</description>
    <arm_group_label>Atomoxetine</arm_group_label>
    <other_name>Straterra</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>40 to 80 mg orally once daily for 8 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of idiopathic Parkinson's disease

          -  IDS score greater than 21

          -  Mini-Mental State Examination (MMSE) score greater than 15

        Exclusion Criteria:

          -  Recent deep brain stimulation

          -  Currently participating in an antidepressant trial at a less than adequate dose and
             duration

          -  Severe depression or depression with suicide ideation

          -  History of liver toxicity

          -  Unstable medical disease or comorbid psychiatric disease
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel Weintraub, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Philadelphia Veterans Affairs Medical Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2918470/pdf/7887.pdf</url>
    <description>Manuscript</description>
  </link>
  <results_reference>
    <citation>Weintraub D, Mavandadi S, Mamikonyan E, Siderowf AD, Duda JE, Hurtig HI, Colcher A, Horn SS, Nazem S, Ten Have TR, Stern MB. Atomoxetine for depression and other neuropsychiatric symptoms in Parkinson disease. Neurology. 2010 Aug 3;75(5):448-55. doi: 10.1212/WNL.0b013e3181ebdd79.</citation>
    <PMID>20679638</PMID>
  </results_reference>
  <verification_date>March 2015</verification_date>
  <lastchanged_date>March 10, 2015</lastchanged_date>
  <firstreceived_date>March 15, 2006</firstreceived_date>
  <firstreceived_results_date>June 12, 2012</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pennsylvania</investigator_affiliation>
    <investigator_full_name>Daniel Weintraub</investigator_full_name>
    <investigator_title>Associate Professor of Psychiatry and Neurology</investigator_title>
  </responsible_party>
  <keyword>Depression</keyword>
  <keyword>Parkinson's Disease</keyword>
  <keyword>Atomoxetine</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Atomoxetine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were recruited from The Parkinson's Disease and Movement Disorders Center at Pennsylvania Hospital and the Parkinson's Disease Research, Education, and Clinical Center at the Philadelphia Veterans Affairs Medical Center between 2004-2009.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Atomoxetine</title>
          <description>Participants will receive 40-80mgs of atomoxetine orally once daily.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Participants will receive placebo treatment once daily; the pill (taken orally) will resemble the atomoxetine pill but will not contain an active drug.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Atomoxetine</title>
          <description>Participants will receive atomoxetine treatment</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Participants will receive placebo treatment</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="28"/>
                <measurement group_id="B2" value="27"/>
                <measurement group_id="B3" value="55"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="14"/>
                <measurement group_id="B2" value="11"/>
                <measurement group_id="B3" value="25"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="14"/>
                <measurement group_id="B2" value="16"/>
                <measurement group_id="B3" value="30"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="63.8" spread="9.5"/>
                <measurement group_id="B2" value="64.9" spread="11.5"/>
                <measurement group_id="B3" value="64.3" spread="10.5"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="8"/>
                <measurement group_id="B2" value="11"/>
                <measurement group_id="B3" value="19"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="20"/>
                <measurement group_id="B2" value="16"/>
                <measurement group_id="B3" value="36"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="28"/>
                <measurement group_id="B2" value="27"/>
                <measurement group_id="B3" value="55"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Inventory of Depressive Symptomatology- Clinician Rated (IDS-C) Scale</title>
        <description>The primary measure of depression symptom severity was the Inventory for Depressive Symptomatology–Clinician Rated (IDS-C), a 30-item (scores 0–84, increasing scores indicating greater depression severity) comprehensive instrument that is increasingly used as a primary outcome measure in major depression treatment studies in the general population. An IDS-C score of greater than or equal to 22 was indicative of at least moderate depression. The IDS-C was administered at every study visit. The criteria for the primary measure of treatment response was a &gt;50% decrease in IDS-C score from baseline.</description>
        <time_frame>Week 8</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Atomoxetine</title>
            <description>Participants will receive 40-80mgs of atomoxetine orally once daily.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants will receive placebo treatment once daily; the pill (taken orally) will resemble the atomoxetine pill but will not contain an active drug.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="22"/>
                  <measurement group_id="O2" value="21"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Inventory of Depressive Symptomatology- Clinician Rated (IDS-C) Scale</title>
            <description>The primary measure of depression symptom severity was the Inventory for Depressive Symptomatology–Clinician Rated (IDS-C), a 30-item (scores 0–84, increasing scores indicating greater depression severity) comprehensive instrument that is increasingly used as a primary outcome measure in major depression treatment studies in the general population. An IDS-C score of greater than or equal to 22 was indicative of at least moderate depression. The IDS-C was administered at every study visit. The criteria for the primary measure of treatment response was a &gt;50% decrease in IDS-C score from baseline.</description>
            <units>percentage of improved participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="22.7"/>
                  <measurement group_id="O2" value="9.5"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Global Impression-Improvement Scale</title>
        <description>The Clinical Global Impression-Improvement scale rates total improvement on a 7 point scale:
= Very much improved
= Much improved
= Minimally improved
= No change
= Minimally worse
= Much worse
= Very much worse
A participant scoring a 1 or 2 is considered a responder on the CGI scale.</description>
        <time_frame>Week 8</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Atomoxetine</title>
            <description>Participants will receive 40-80mgs of atomoxetine orally once daily.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants will receive placebo treatment once daily; the pill (taken orally) will resemble the atomoxetine pill but will not contain an active drug.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="22"/>
                  <measurement group_id="O2" value="21"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Clinical Global Impression-Improvement Scale</title>
            <description>The Clinical Global Impression-Improvement scale rates total improvement on a 7 point scale:
= Very much improved
= Much improved
= Minimally improved
= No change
= Minimally worse
= Much worse
= Very much worse
A participant scoring a 1 or 2 is considered a responder on the CGI scale.</description>
            <units>percentage of responders</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="45.5"/>
                  <measurement group_id="O2" value="33.3"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Atomoxetine</title>
          <description>Participants will receive 40-80mgs of atomoxetine orally once daily.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Participants will receive placebo treatment once daily; the pill (taken orally) will resemble the atomoxetine pill but will not contain an active drug.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Congestive Heart Failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Suicide Ideation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Nausea/Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>First, the sample size was relatively small. Second, the diagnostic criteria for depression which are typically used in clinical trials were not used as an inclusion criterion. Third, antidepressant use at baseline was common in our population.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Daniel Weintraub</name_or_title>
      <organization>University of Pennsylvania</organization>
      <phone>215-349-8207</phone>
      <email>daniel.weintraub@uphs.upenn.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
